Group 1 - The company holds a 0.75% stake in Replicor through its wholly-owned subsidiary, Laimei Hong Kong [2] - Replicor's hepatitis B drug development project is progressing steadily, and the company will closely monitor the project's subsequent developments [2] - The company will fulfill its information disclosure obligations in accordance with relevant regulations from the Shenzhen Stock Exchange [2]